Influence of left ventricular ejection fraction in patients undergoing contemporary pLVAD-supported high-risk PCI
Abu-Much A, Grines C, Batchelor W, Maini A, Zhang Y, Redfors B, Bellumkonda L, Bharadwaj A, Moses J, Truesdell A, Li Y, Baron S, Lansky A, Basir M, Cohen D, O'Neill W. Influence of left ventricular ejection fraction in patients undergoing contemporary pLVAD-supported high-risk PCI. American Heart Journal 2023, 269: 139-148. PMID: 38151142, DOI: 10.1016/j.ahj.2023.12.015.Peer-Reviewed Original ResearchBaseline LV ejection fractionLV ejection fractionPercutaneous coronary interventionPCI-related complicationsLV dysfunctionEjection fractionLV functionLeft main percutaneous coronary interventionHigh-risk percutaneous coronary interventionHigh-risk PCI patientsImmediate percutaneous coronary interventionMain percutaneous coronary interventionModerate LV dysfunctionSevere LV dysfunctionVentricular systolic dysfunctionVentricular ejection fractionCoronary complicationsLVEF groupMACCE rateCerebrovascular eventsPCI patientsSystolic dysfunctionCoronary interventionIII studyMyocardial infarctionTCT-214 Right Ventricular Function in Patients Undergoing Impella-Assisted High-Risk Percutaneous Coronary Intervention: Insights From the cVAD PROTECT III Study
Rommel K, Bonnet G, Bellumkonda L, Zhang Y, Lansky A, Redfors B, Granada J, Bharadwaj A, Basir B, Patel R, O’Neill W, Burkhoff D. TCT-214 Right Ventricular Function in Patients Undergoing Impella-Assisted High-Risk Percutaneous Coronary Intervention: Insights From the cVAD PROTECT III Study. Journal Of The American College Of Cardiology 2023, 82: b82-b83. DOI: 10.1016/j.jacc.2023.09.221.Peer-Reviewed Original ResearchImpella Utilization in High-Risk Percutaneous Coronary Intervention Mitigates the Risks of Procedural and Clinical Adverse Events Independent of Left Ventricular Ejection Fraction: The Protect III Study
Abu-Much A, Maini A, Grines C, Bharadwaj A, Moses J, Zhang Y, Redfors B, Bellumkonda L, Li Y, Truesdell A, Baron S, Lansky A, Basir M, O'Neill W. Impella Utilization in High-Risk Percutaneous Coronary Intervention Mitigates the Risks of Procedural and Clinical Adverse Events Independent of Left Ventricular Ejection Fraction: The Protect III Study. Cardiovascular Revascularization Medicine 2023, 53: s126. DOI: 10.1016/j.carrev.2023.05.290.Peer-Reviewed Original ResearchCRT-700.05 Impella Utilization in High-Risk Percutaneous Coronary Intervention Mitigates the Risks of Procedural and Clinical Adverse Events Independent of Left Ventricular Ejection Fraction: The Protect III Study
Abu-Much A, Maini A, Grines C, Bharadwaj A, Moses J, Zhang Y, Redfors B, Bellumkonda L, Li Y, Truesdell A, Baron S, Lansky A, Basir M, O'Neill W. CRT-700.05 Impella Utilization in High-Risk Percutaneous Coronary Intervention Mitigates the Risks of Procedural and Clinical Adverse Events Independent of Left Ventricular Ejection Fraction: The Protect III Study. JACC Cardiovascular Interventions 2023, 16: s107. DOI: 10.1016/j.jcin.2023.01.337.Peer-Reviewed Original Research